Pfizer releases data on oral COVID-19 antiviral treatment candidate, says pill reduces risk of hospitalization or death by 89%
Pfizer today the first phase 2/3 clinical trial data on its oral COVID-19 antiviral treatment, declaring its candidate to be highly effective in reducing the risk of hospitalization or death from severe COVID-19. Pfizer said the drug, Paxlovid, when administered within five days of the appearance of COVID-19 symptoms, yielded an 89% reduction in deaths or hospitalizations through 28 days. Pfizer said it will submit the data to the Food and Drug Administration in support of its rolling submission for an emergency use authorization.
Related News Articles
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
CDC recommends two doses of COVID-19 vaccine for older individuals, lowers pneumococcal vaccine ageÂ
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…